American Conference Institute will hold its fifth annual “Pharma/Biotech IP Due Diligence” conference January 30-31 in New York. ACI describes this conference as the “complete guide for M&As, licensing and other collaborations.”
The agenda includes several talks that sound especially interesting, including:
- “Factoring Patent Reform, PTO Rulemaking and New Case Law Into Your Due Diligence Analysis”
- “Managing Due Diligence When Dealing with Industry/University Collaborations and Licenses”
- “Evaluating the Scope, Validity, and Enforceability of the Target’s Patents”
- “Freedom to Operate: Ensuring the Purchaser/Licensee Has the Right to Commercialize the IP at Issue”
- “FDA Regulation of Small Molecule Drugs and Biologics: Understanding How This Affects the Diligence Review”
In addition, ACI is offering an optional master class on February 1, entitled “Drafting an Effective Due Diligence Report.”
For more information or to register, please visit the conference website.
Orange Book Blog is a media partner of this conference.
Orange Book Blog 
Leave a comment